Market Access Manager, EU Center

You will report to the Senior Director, Market Access, EU Center and work closely with Medical Affairs, HEOR, Regulatory, Commercial and our global Market Access team to secure and sustain patient access to BridgeBio's medicines across the DACH region. Your remit is to own the German AMNOG process end to end and regional market access. You will also lead reimbursement submissions in Austria and Switzerland.

Responsibilities

Lead AMNOG value dossiers end to end under § 35a SGB V, including comparator therapy derivation, evidence gap identification and indirect comparison, surrogate and subgroup argumentation; Own G-BA and IQWiG interactions, including scientific advice requests under § 8 AM-NutzenV, written commenting procedures and oral hearings; Prepare and support price negotiations with the GKV-Spitzenverband under § 130b SGB V, including pricing strategy, negotiation mandate, scenarios and European reference price analyses; Drive regional payer engagement with sickness funds, the Medical Service and regional physicians' associations; Secure hospital and clinic reimbursement, including NUB, DRG and additional-payment mapping, budget negotiations and ASV under § 116b SGB V; Resolve access barriers in the field, including individual reimbursement requests, denials and claw-backs; Lead reimbursement submissions in Austria (EKO) and Switzerland (FOPH Specialities List); Bring market access requirements into study design, evidence planning and launch planning

Requirements

Degree in health economics, pharmacy, medicine, life sciences or a comparable field; 5–8 years of experience in market access or HTA in the pharmaceutical industry, a consultancy or a specialised HTA service provider; Demonstrated experience preparing AMNOG value dossiers under § 35a SGB V, ideally as project lead on at least one complete procedure; Hands-on involvement in a reimbursement price negotiation under § 130b SGB V; Solid command of G-BA and IQWiG methodology, procedural rules and statutory timelines; Ability to appraise clinical evidence critically and translate it into payer-ready argumentation; Experience engaging payers and/or hospitals directly on reimbursement matters; Strong written argumentation; Ability to work autonomously in an environment where some processes are still being built; Business-fluent German and English; Willingness to travel approximately 20% of working time

Nice to have

Experience with orphan drugs or a limited evidence base; Knowledge of German hospital financing (NUB, DRG, additional payments); Knowledge of reimbursement in Austria and Switzerland

Benefits

Market-leading compensation; Hybrid work model; Career development through regular feedback, continuous education and professional development programs; Financial rewards, peer-to-peer recognition and growth opportunities